However, specific concentrations (50 μM in CML cells [33], 20 μM in ALL cells [34], 5 μM retinoblastoma cells [41], 1 μM in cervical squamous cell carcinoma cells [32], 10 μM in NSCLC cells [28], 2.5 μM in Myc-driven lymphoma cells [37], and 2.5 μM in ovarian cancer cells [39]) of tigecycline treatment induces significant intrinsic apoptosis by activating the intrinsic apoptosis pathway, with activation of BCL-2, release of cytochrome c, and cleavage of caspase-9/caspase-3/caspase-7. The gene discussed is MYC; the disease is ovarian cancer.